FDA Approves Regeneron's First Gene Therapy to Restore Hearing in Deaf Children

Regeneron has received FDA approval for the first gene therapy targeting a rare genetic form of deafness, with plans to offer it free of charge. This approval could revolutionize treatment options for inherited hearing loss, impacting around 50 babies annually in the US. Future research will likely focus on expanding gene therapy applications for other genetic conditions affecting hearing.